Phillip  Frost net worth and biography

Phillip Frost Biography and Net Worth

CEO of OPKO Health

Dr. Phillip Frost is the chairman and CEO at OPKO Health, Inc., a biopharmaceutical and diagnostics company. 

Dr. Frost was born in Philadelphia in 1936. He earned his undergraduate degree at the University of Pennsylvania, and his M.D. at the Albert Einstein College of Medicine.

Following university, he served as a lieutenant commander for the U.S. Public Health Service at the National Cancer Institute. He then worked as a dermatology professor at the University of Miami School of Medicine, and later served as chair of Mt. Sinai Medical Center’s dermatology department. 

Frost joined Key Pharmaceuticals in 1972, where he reformulated its asthma drug and then sold the company for $836 million in 1986. He served as chair and CEO for generic drugmaker, Ivax, from 1987 to 2006, when it was acquired by Teva Pharmaceutical Industries. He sat on Teva’s board until 2015.

Presently, Dr. Frost serves as OPKO Health’s CEO, a role he has held since 2007. The company is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products.

Dr. Frost is also a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.

In September 2018, the SEC accused Dr. Frost of participating in a "pump-and-dump" scheme that generated over $27 million in unlawful stock sales. He settled in December 2018 without admitting or denying the allegations.

Dr. Frost sits on numerous boards and has a long history of philanthropy. His financial gifts include a $33 million donation to the University of Miami School of Music in 2003, then the largest gift to a university music school in the U.S. The school was subsequently renamed the Phillip and Patricia Frost School of Music. In 2011, he gave $35 million for the construction of a new building for the Miami Science Museum, to be named the Patricia & Phillip Frost Science Museum, and in 2015, he gave an additional $10 million toward the museum’s Frost Planetarium.

He is married to Patrica Orr, and they live on Star Island, Miami Beach.

What is Phillip Frost's net worth?

The estimated net worth of Phillip Frost is at least $385.37 million as of March 17th, 2025. Dr. Frost owns 213,501,448 shares of OPKO Health stock worth more than $385,370,114 as of March 25th. This net worth evaluation does not reflect any other assets that Dr. Frost may own. Additionally, Dr. Frost receives an annual salary of $1,450,000.00 as CEO at OPKO Health. Learn More about Phillip Frost's net worth.

How old is Phillip Frost?

Dr. Frost is currently 88 years old. There are 7 older executives and no younger executives at OPKO Health. Learn More on Phillip Frost's age.

What is Phillip Frost's salary?

As the CEO of OPKO Health, Inc., Dr. Frost earns $1,450,000.00 per year. Learn More on Phillip Frost's salary.

How do I contact Phillip Frost?

The corporate mailing address for Dr. Frost and other OPKO Health executives is 4400 BISCAYNE BLVD., MIAMI FL, 33137. OPKO Health can also be reached via phone at (305) 575-4100 and via email at mmiller@lhai.com. Learn More on Phillip Frost's contact information.

Has Phillip Frost been buying or selling shares of OPKO Health?

Within the last three months, Phillip Frost has bought $1,493,691.53 of OPKO Health stock. Most recently, on Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,501,448 shares of the company's stock, valued at $371,492,519.52. Learn More on Phillip Frost's trading history.

Who are OPKO Health's active insiders?

OPKO Health's insider roster includes Jon Cohen (SVP), and Phillip Frost (CEO). Learn More on OPKO Health's active insiders.

Are insiders buying or selling shares of OPKO Health?

In the last twelve months, OPKO Health insiders bought shares 13 times. They purchased a total of 2,533,223 shares worth more than $3,856,852.32. In the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 736,644 shares worth more than $23,874,134.15. The most recent insider tranaction occured on March, 17th when CEO Phillip Md Et Al Frost bought 200,000 shares worth more than $348,000.00. Insiders at OPKO Health own 47.3% of the company. Learn More about insider trades at OPKO Health.

Information on this page was last updated on 3/17/2025.

Phillip Frost Insider Trading History at OPKO Health

Phillip Frost Buying and Selling Activity at OPKO Health

This chart shows Phillip Md Et Al Frost's buying and selling at OPKO Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$1.49Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal Insider BuyingTotal Insider Selling

OPKO Health Company Overview

OPKO Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $1.80
Low: $1.78
High: $1.81

50 Day Range

MA: $1.66
Low: $1.47
High: $1.94

2 Week Range

Now: $1.80
Low: $0.99
High: $2.04

Volume

1,722,168 shs

Average Volume

4,224,167 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7